Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Trillium Therapeutics, a privately held biopharmaceutical company, has announced Michael Berendt and John Dietrich have joined its board as independent directors.
Subscribe to our email newsletter
Dr Berendt is currently a director of Waters Corporation and has served on the board of directors of numerous other life sciences companies. Dr Berendt has received a doctoral degree in medical microbiology and immunology from Hahnemann University.
Dr Dietrich joined Ventrus Biosciences in April 2007, where he currently serves as vice president of clinical operations. Dr Dietrich has received his PhD in pharmacology from the University of North Carolina at Chapel Hill.
Michael Moore, chairman of Trillium, said: “It is a great pleasure to welcome these two experienced biotech executives to the board where they will enhance our capabilities in strategic planning and product development. Their appointments are commensurate with completion of an internal financing round of $12 million and the entry into clinical development of Trillium’s lead product, TTI-1612.”